Spinoff and activist will benefit Glaxo

Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company… Read More

The U.K. is looking beyond Brexit and COVID

Last year was a difficult one for the U.K. and its economy due the coronavirus pandemic. But the outlook for 2021 is much more positive.
The rebound will come from the easing of COVID-19 restrictions as the pandemic slows and from the government’s extensive stimulus spending… Read More

Pfizer remains our top drug stock

We now see several promising opportunities emerging in the pharmaceutical drug industry, and we will probably recommend more drug stocks in the next few years. For now, we feel Pfizer offers our readers the best combination of growth and income in a pharma stock. Since… Read More

A great choice for COVID-19 gains

PFIZER INC. $37 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $207.2 billion; Price-to-sales ratio: 4.1; Dividend yield: 4.1%; TSINetwork Rating: Above Average; www.pfizer.com) saw its revenue in the first quarter of 2020 fall 8.3%,… Read More

You’ll profit from Pfizer’s new focus

Under a new long-term strategy, Pfizer is concentrating on what it does best: developing new patented drugs that generate strong returns for its shareholders.
As part of that plan, the company is merging its over-the-counter and generic drugs businesses with those of other pharmaceutical firms to… Read More